Australia Launches World’s Largest Medicinal Cannabis Study to Assess Economic Impact on Chronic Health Conditions

Researchers in Australia are embarking on a groundbreaking investigation into the potential economic benefits of medicinal cannabis as a treatment for chronic health conditions. This study, known as the QUEST Global study, is set to become the world's largest exploration of how medicinal cannabis impacts health economic outcomes and the quality of life for individuals enduring chronic health conditions.

Individuals in Australia living with one of 200 chronic health conditions may now qualify to participate in this study. The QUEST Global study is spearheaded by researchers from Curtin University and is sponsored by Little Green Pharma (LGP), a supplier of medicinal cannabis. It also receives support from the Health Insurance Fund of Australia (HIF), marking the first Australian health fund to openly endorse medicinal cannabis treatments and offer rebates on related products.

Building upon the achievements of the initial QUEST Initiative, this study aims to assess whether medicinal cannabis can alleviate the economic burden of chronic diseases by potentially reducing the number of medications needed by patients and diminishing their reliance on healthcare services.

Early findings from the QUEST Initiative have already showcased significant enhancements in various quality-of-life indicators among participants. These improvements encompass mobility, functionality, pain management, sleep quality, and reductions in anxiety and depression symptoms.

QUEST Global will delve even deeper into the assessment of health economic outcomes. It will scrutinize the potential for medicinal cannabis to not only decrease the quantity of medications required by patients but also curtail their dependence on healthcare services.

This comprehensive study is scheduled to span five years and welcomes participants without any set limit on numbers. Associate Professor Richard Norman, the lead researcher from Curtin's School of Population Health, emphasizes that QUEST Global aims to confront the very real health challenges faced by many individuals dealing with chronic conditions. Medicinal cannabis is seen as a promising treatment option to enhance outcomes and alleviate suffering.

As part of the study, participants will have access to pharmaceutical-grade cannabis oils and flower medications produced locally. Additionally, they can consult with a variety of experienced medical cannabis prescribers at an affordable cost.

Dr. Leon Warne, Head of Research and Innovation at LGP, expresses excitement about this collaboration with Curtin, known for its high-quality research with real-world impact. He highlights that QUEST Global will not only evaluate changes in participants' conditions and symptoms but also delve into the economic aspects of health. This will offer insights into how Australia can efficiently allocate its limited health resources to meet the demands and needs of its populace for healthcare services, health promotion, and prevention.